1.14

5.79% -0.07

After Hours: 1.14

Calidi Biotherapeutics Inc (CLDI)

Overview News Price History Discussions Forecast

Calidi Biotherapeutics Inc stock is traded at $1.14, with a volume of 210.02K. It is down -5.79% in the last 24 hours and up +0.00% over the past month. Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.

Previous Close:

$1.21

Open:

$1.22

24h Volume:

210.02K

Relative Volume:

1.06

Market Cap:

$9.70M

Revenue:

Net Income/Loss:

$-23.36M

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+2.70%

1M Performance:

+0.00%

6M Performance:

-79.82%

1Y Performance:

-96.57%

1-Day Range:

$1.10

$1.23

1-Week Range:

$1.10

$1.23

52-Week Range:

$1.01

$33.20

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Name

Calidi Biotherapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(858) 794-9600

Address

4475 Executive Drive, Suite 200, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CLDI's Discussions on Twitter

Calidi Biotherapeutics Inc Stock (CLDI) Latest News

09:45 AM

Calidi Biotherapeutics Gains FDA Nod for Brain Cancer Trial - TipRanks

09:45 AM

09:04 AM

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 - U.S. Politics Today

09:04 AM

08:09 AM

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma - The Manila Times

08:09 AM

08:02 AM

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application - The Bakersfield Californian

08:02 AM

08:00 AM

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma - StockTitan

08:00 AM

Sep 24, 2024

Calidi Biotherapeutics announces board changes and auditor ratification - Investing.com

Sep 24, 2024

Sep 12, 2024

Calidi Biotherapeutics Presents Antitumor Virotherapy Advances - TipRanks

Sep 12, 2024

Sep 09, 2024

Calidi Biotherapeutics stock target cut by Baird with Outperform tag maintained - Investing.com

Sep 09, 2024

Calidi price target lowered to $2.50 from $20 at Baird - TipRanks

Sep 09, 2024

Aug 26, 2024

CLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q2 2024 - MSN

Aug 26, 2024